5-[{4-[(4-butylphenyl)ethynyl]benzyl}-(hexyl)amino]-2-hydroxybenzoic acid

ID: ALA4063482

Chembl Id: CHEMBL4063482

Cas Number: 866931-06-8

PubChem CID: 11497282

Max Phase: Preclinical

Molecular Formula: C32H37NO3

Molecular Weight: 483.65

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CCCCCCN(Cc1ccc(C#Cc2ccc(CCCC)cc2)cc1)c1ccc(O)c(C(=O)O)c1

Standard InChI:  InChI=1S/C32H37NO3/c1-3-5-7-8-22-33(29-20-21-31(34)30(23-29)32(35)36)24-28-18-16-27(17-19-28)15-14-26-12-10-25(11-13-26)9-6-4-2/h10-13,16-21,23,34H,3-9,22,24H2,1-2H3,(H,35,36)

Standard InChI Key:  FQMKKDYJAKJVRO-UHFFFAOYSA-N

Associated Targets(Human)

THP-1 (11052 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PTPRO Tbio Receptor-type tyrosine-protein phosphatase O (15 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PTPN11 Tchem Protein-tyrosine phosphatase 2C (2297 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 483.65Molecular Weight (Monoisotopic): 483.2773AlogP: 7.42#Rotatable Bonds: 12
Polar Surface Area: 60.77Molecular Species: ACIDHBA: 3HBD: 2
#RO5 Violations: 1HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: 2.05CX Basic pKa: 5.96CX LogP: 7.89CX LogD: 6.75
Aromatic Rings: 3Heavy Atoms: 36QED Weighted: 0.21Np Likeness Score: -0.38

References

1.  (2011)  GLEPP-1 inhibitors in the treatment of autoimmune and/or inflammatory disorders, 
2. Shen D, Chen W, Zhu J, Wu G, Shen R, Xi M, Sun H..  (2020)  Therapeutic potential of targeting SHP2 in human developmental disorders and cancers.,  190  [PMID:32061959] [10.1016/j.ejmech.2020.112117]